Ocular Therapeutix (NSDQ:OCUL) said today that its post-surgical ocular pain reliever, Dextenza, met both primary endpoints in a pivotal trial for the treatment of post-surgical ocular inflammation and pain. The product is a bioresorbable intracanalicular insert, designed for drug release to the ocular surface for up to 30 days.
The randomized, double-masked study enrolled 438 patients who were undergoing clear corneal cataract surgery at 21 sites throughout the U.S to compare the Dextenza insert with a sham control procedure.
Get the full story at our sister site, Drug Delivery Business News.
The post OCUL’s Dextenza meets endpoints in pivotal study appeared first on MassDevice.
from MassDevice http://ift.tt/2eTCsse
Cap comentari:
Publica un comentari a l'entrada